Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Receivables - Net: 2017-2021

Historic Receivables - Net for Protagonist Therapeutics (PTGX) over the last 3 years, with Mar 2021 value amounting to $100,000.

  • Protagonist Therapeutics' Receivables - Net fell 66.67% to $100,000 in Q1 2021 from the same period last year, while for Mar 2021 it was $100,000, marking a year-over-year decrease of 66.67%. This contributed to the annual value of $300,000 for FY2019, which is 2.91% down from last year.
  • As of Q1 2021, Protagonist Therapeutics' Receivables - Net stood at $100,000, which was down 0.00% from $100,000 recorded in Q2 2020.
  • Over the past 5 years, Protagonist Therapeutics' Receivables - Net peaked at $700,000 during Q3 2019, and registered a low of $19,000 during Q2 2017.
  • In the last 3 years, Protagonist Therapeutics' Receivables - Net had a median value of $300,000 in 2020 and averaged $292,286.
  • In the last 5 years, Protagonist Therapeutics' Receivables - Net spiked by 459.38% in 2019 and then plummeted by 72.07% in 2020.
  • Over the past 5 years, Protagonist Therapeutics' Receivables - Net (Quarterly) stood at $58,000 in 2017, then soared by 432.76% to $309,000 in 2018, then dropped by 2.91% to $300,000 in 2019, then tumbled by 72.07% to $100,000 in 2020, then slumped by 66.67% to $100,000 in 2021.
  • Its Receivables - Net was $100,000 in Q1 2021, compared to $100,000 in Q2 2020 and $300,000 in Q1 2020.